Advances in nucleic acid-based cancer vaccines
Abstract Nucleic acid vaccines have emerged as crucial advancements in vaccine technology, particularly highlighted by the global response to the COVID-19 pandemic. The widespread administration of mRNA vaccines against COVID-19 to billions globally marks a significant milestone. Furthermore, the ap...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Journal of Biomedical Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12929-024-01102-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585497270026240 |
|---|---|
| author | Hung-Chun Liao Shih-Jen Liu |
| author_facet | Hung-Chun Liao Shih-Jen Liu |
| author_sort | Hung-Chun Liao |
| collection | DOAJ |
| description | Abstract Nucleic acid vaccines have emerged as crucial advancements in vaccine technology, particularly highlighted by the global response to the COVID-19 pandemic. The widespread administration of mRNA vaccines against COVID-19 to billions globally marks a significant milestone. Furthermore, the approval of an mRNA vaccine for Respiratory Syncytial Virus (RSV) this year underscores the versatility of this technology. In oncology, the combination of mRNA vaccine encoding neoantigens and immune checkpoint inhibitors (ICIs) has shown remarkable efficacy in eliciting protective responses against diseases like melanoma and pancreatic cancer. Although the use of a COVID-19 DNA vaccine has been limited to India, the inherent stability at room temperature and cost-effectiveness of DNA vaccines present a viable option that could benefit developing countries. These advantages may help DNA vaccines address some of the challenges associated with mRNA vaccines. Currently, several trials are exploring the use of DNA-encoded neoantigens in combination with ICIs across various cancer types. These studies highlight the promising role of nucleic acid-based vaccines as the next generation of immunotherapeutic agents in cancer treatment. This review will delve into the recent advancements and current developmental status of both mRNA and DNA-based cancer vaccines. |
| format | Article |
| id | doaj-art-6762d06f11ec41e4b5199656301cfdb2 |
| institution | Kabale University |
| issn | 1423-0127 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Biomedical Science |
| spelling | doaj-art-6762d06f11ec41e4b5199656301cfdb22025-01-26T12:46:15ZengBMCJournal of Biomedical Science1423-01272025-01-0132112810.1186/s12929-024-01102-wAdvances in nucleic acid-based cancer vaccinesHung-Chun Liao0Shih-Jen Liu1National Institute of Infectious Diseases and Vaccinology, National Health Research InstitutesNational Institute of Infectious Diseases and Vaccinology, National Health Research InstitutesAbstract Nucleic acid vaccines have emerged as crucial advancements in vaccine technology, particularly highlighted by the global response to the COVID-19 pandemic. The widespread administration of mRNA vaccines against COVID-19 to billions globally marks a significant milestone. Furthermore, the approval of an mRNA vaccine for Respiratory Syncytial Virus (RSV) this year underscores the versatility of this technology. In oncology, the combination of mRNA vaccine encoding neoantigens and immune checkpoint inhibitors (ICIs) has shown remarkable efficacy in eliciting protective responses against diseases like melanoma and pancreatic cancer. Although the use of a COVID-19 DNA vaccine has been limited to India, the inherent stability at room temperature and cost-effectiveness of DNA vaccines present a viable option that could benefit developing countries. These advantages may help DNA vaccines address some of the challenges associated with mRNA vaccines. Currently, several trials are exploring the use of DNA-encoded neoantigens in combination with ICIs across various cancer types. These studies highlight the promising role of nucleic acid-based vaccines as the next generation of immunotherapeutic agents in cancer treatment. This review will delve into the recent advancements and current developmental status of both mRNA and DNA-based cancer vaccines.https://doi.org/10.1186/s12929-024-01102-wDNA vaccinemRNA vaccineCancer vaccineNeoantigen |
| spellingShingle | Hung-Chun Liao Shih-Jen Liu Advances in nucleic acid-based cancer vaccines Journal of Biomedical Science DNA vaccine mRNA vaccine Cancer vaccine Neoantigen |
| title | Advances in nucleic acid-based cancer vaccines |
| title_full | Advances in nucleic acid-based cancer vaccines |
| title_fullStr | Advances in nucleic acid-based cancer vaccines |
| title_full_unstemmed | Advances in nucleic acid-based cancer vaccines |
| title_short | Advances in nucleic acid-based cancer vaccines |
| title_sort | advances in nucleic acid based cancer vaccines |
| topic | DNA vaccine mRNA vaccine Cancer vaccine Neoantigen |
| url | https://doi.org/10.1186/s12929-024-01102-w |
| work_keys_str_mv | AT hungchunliao advancesinnucleicacidbasedcancervaccines AT shihjenliu advancesinnucleicacidbasedcancervaccines |